지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 86 - 93 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years and to clarify whether an extremely high sustained virological response (SVR) rate can be achieved, even in a real-world setting when patients with resistance-associated substitutions (RASs) to nonstructural protein 5A (NS5A) inhibitors or prior simeprevir failure are excluded. Methods: Daclatasvir (60 mg) and asunaprevir (100 mg) were orally administered daily for 24 weeks. Patients without pre-existing NS5A RASs and simeprevir failure were enrolled in this study. Results: Overall, 110 patients were treated. The median age was 73 years old. The SVR rates of total patients, those aged ≥75 years, and those aged <75 years were 97% (107/110), 98% (46/47), and 97% (61/63), respectively. The treatment of two patients (2%) was discontinued because of adverse events. Conclusions: Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years. When patients without pre-existing NS5A RASs and prior simeprevir failure were selected, an extremely high SVR rate could be achieved irrespective of age.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Asahina Y / 2010 / Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection / Hepatology 52:518~527
Editors of the Drafting Committee for Hepatitis Management Guidelines / 2013 / Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology / Hepatol Res 43:1~34
Tamai H / 2011 / Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation / Hepatol Res 41:1137~1144
Tamai H / 2014 / Low-dose pegylated interferon-${\alpha}2a$ plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load / Antivir Ther 19:107~115
Kumada H / 2012 / Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan / J Hepatol 56:78~84
Editors of the Drafting Committee for Hepatitis Management Guidelines / 2013 / Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology / Hepatol Res 43:1~34
Tamai H / 2011 / Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation / Hepatol Res 41:1137~1144
Tamai H / 2014 / Low-dose pegylated interferon-
Kumada H / 2012 / Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan / J Hepatol 56:78~84
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
고령의 만성 C형 간염 환자에서 Daclatasvir와 Asunaprevir 병용 요법의 유효성 및 안전성 평가
병원약사회지
2018 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Clinical and Molecular Hepatology
2023 .04
-
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
Gut and Liver
2019 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Clinical and Molecular Hepatology
2017 .01
-
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
Gut and Liver
2017 .07
-
Patient acceptability and efficacy of simeprevir and sofosbuvir in hepatitis C after allogeneic stem cell transplantation
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
Clinical and Molecular Hepatology
2016 .01
-
포커스 그룹 인터뷰를 이용한 환자안전전담자의 환자 및 보호자 대상 환자 안전 교육 경험 분석
한국의료질향상학회지
2019 .01
-
의원급 의료기관 환자의 환자경험과 환자안전인식의 관계에서 환자안전지식의 조절효과
성인간호학회지
2021 .08
-
An Exploration Into Patients’ Experiences That Make Them Feel Safe During Hospitalization: A Qualitative Study
Journal of Korean Medical Science
2022 .08
-
의과대학생을 위한 환자안전 교육의 국제적 동향 및 국내 현황
의학교육논단
2019 .01
-
국내 환자안전사고 관련 요인 분석
간호행정학회지
2020 .03
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Clinical outcome for laparoscopic cholecystectomy in extremely elderly patients
Annals of Surgical Treatment and Research
2015 .02
-
간호사의 환자안전문화 인식이 환자안전사건 보고에 미치는 영향
간호행정학회지
2018 .09
-
위해사건 예방을 위한 수술 환자 교육용 스마트폰 애플리케이션의 효과
성인간호학회지
2017 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0